Nexthera Capital L.P. 13F annual report

Nexthera Capital L.P. is an investment fund managing more than $120 million ran by Daniel Malek. There are currently 23 companies in Mr. Malek’s portfolio. The largest investments include Intercept Pharmaceuticals and Insmed, together worth $24.2 million.

$120 million Assets Under Management (AUM)

As of 7th October 2020, Nexthera Capital L.P.’s top holding is 152,441 shares of Intercept Pharmaceuticals currently worth over $12.1 million and making up 10.1% of the portfolio value. Relative to the number of outstanding shares of Intercept Pharmaceuticals, Nexthera Capital L.P. owns more than approximately 0.1% of the company. In addition, the fund holds 470,741 shares of Insmed worth $12.1 million, whose value grew 93.7% in the past six months. The third-largest holding is Audentes Therapeutics Inc worth $11.1 million and the next is Neurocrine Biosciences worth $7.8 million, with 92,380 shares owned.

Currently, Nexthera Capital L.P.'s portfolio is worth at least $120 million. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.

Careers at Nexthera Capital L.P.

The Nexthera Capital L.P. office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Daniel Malek serves as the Managing Member/CEO at Nexthera Capital L.P..

Recent trades

In the most recent 13F filing, Nexthera Capital L.P. revealed that it had opened a new position in Coherus BioSciences and bought 316,316 shares worth $6.99 million. This means they effectively own approximately 0.1% of the company. Coherus BioSciences makes up 6.8% of the fund's Health Care sector allocation and has grown its share price by 4.8% in the past year.

The investment fund also strengthened its position in Intercept Pharmaceuticals by buying 140,489 additional shares. This makes their stake in Intercept Pharmaceuticals total 152,441 shares worth $12.1 million. Intercept Pharmaceuticals dropped 42.5% in the past year.

On the other hand, there are companies that Nexthera Capital L.P. is getting rid of from its portfolio. Nexthera Capital L.P. closed its position in Heron Therapeutics on 14th August 2019. It sold the previously owned 388,623 shares for $9.5 million. Daniel Malek also disclosed a decreased stake in Allergan Plc by 0.8%. This leaves the value of the investment at $560 thousand and 3,347 shares.

One of the smallest hedge funds

The two most similar investment funds to Nexthera Capital L.P. are Moseley Investment Management Inc and Searcy Financial Services Inc adv. They manage $120 million and $120 million respectively.

Daniel Malek investment strategy

Nexthera Capital L.P.’s portfolio is diversified across 2 sectors. Currently, their heaviest sector is Health Care — making up 86.0% of the total portfolio value. The fund focuses on investments in the United States as 65.2% of the portfolio companies are based in the United States.

The majority of the companies in the fund’s portfolio are large-cap stocks. Stocks with a size of more than $10 billion in market cap make up 22% of the total holdings value. On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio. The average market cap of the portfolio companies is close to $19.3 billion.

The complete list of Nexthera Capital L.P. trades based on 13F SEC filings

These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.

Security	Shares Owned	Value	Allocation
Intercept Pharmaceuticals, Inc.	1,175.44% 152,441	$12,130,000	10.10%
Insmed, Inc.	65.60% 470,741	$12,051,000	10.04%
Audentes Therapeutics Inc	17.31% 294,013	$11,131,000	9.27%
Heron Therapeutics, Inc.	Closed 388,623	$9,498,000
Neurocrine Biosciences, Inc.	284.28% 92,380	$7,800,000	6.50%
Sarepta Therapeutics, Inc.	136.56% 50,317	$7,646,000	6.37%
Global Blood Therapeutics, Inc.	63.38% 142,305	$7,485,000	6.23%
Immunomedics, Inc.	56.59% 524,140	$7,270,000	6.06%
Coherus BioSciences, Inc.	Opened 316,316	$6,991,000	5.82%
Ascendis Pharma A/S	Opened 60,266	$6,940,000	5.78%
Pacira Biosciences, Inc.	Opened 149,086	$6,484,000	5.40%
UroGen Pharma Ltd.	33.39% 176,866	$6,357,000	5.29%
Bausch Health Cos., Inc.	Closed 205,660	$5,080,000
uniQure NV	54.34% 59,883	$4,680,000	3.90%
Amarin Corp. Plc	54.88% 230,295	$4,465,000	3.72%
Stemline Therapeutics, Inc.	Closed 325,526	$4,183,000
Novartis AG	Closed 45,329	$3,834,000
AbbVie, Inc.	Opened 52,681	$3,831,000	3.19%
Biohaven Pharmaceutical Holdin	Opened 86,165	$3,773,000	3.14%
CymaBay Therapeutics, Inc.	Closed 210,257	$2,792,000
Exelixis, Inc.	Closed 90,356	$2,150,000
Acorda Therapeutics, Inc.	Closed 154,806	$2,057,000
Mylan NV	Opened 102,560	$1,953,000	1.63%
Intra-Cellular Therapies, Inc.	Opened 143,665	$1,865,000	1.55%
Regeneron Pharmaceuticals, Inc.	Opened 5,668	$1,774,000	1.48%
Madrigal Pharmaceuticals, Inc.	346.78% 15,423	$1,616,000	1.35%
Dermira Inc	Opened 138,102	$1,320,000	1.10%
Gilead Sciences, Inc.	Opened 18,697	$1,263,000	1.05%
Kiniksa Pharmaceuticals Ltd.	Closed 67,692	$1,223,000
Chiasma, Inc.	Closed 203,948	$1,061,000
Deciphera Pharmaceuticals, Inc.	Closed 42,865	$995,000
SAGE Therapeutics, Inc.	Closed 6,200	$986,000
BioMarin Pharmaceutical, Inc.	Closed 8,250	$733,000
AnaptysBio, Inc.	Opened 12,026	$679,000	0.57%
Allergan Plc	75.57% 3,347	$560,000	0.47%
No transactions found
Showing first 500 out of 35 holdings